1. Pink Sheet
  2. >>Geography
  3. >>Europe

German Pharma Strategy Promises Drug Pricing Review & Stronger R&D Environment

 
• By Francesca Bruce

The move is intended to boost German innovation in the pharmaceutical area, but some say the impact of the strategy remains “uncertain.”

German government sets out direction of travel for improving ecosystem for the pharmaceutical industry • Source: Shutterstock

The German government has published its much anticipated pharmaceutical strategy, which undertakes to reevaluate the Amnog drug pricing system, reduce bureaucracy and make Germany a better place to conduct clinical trials.

“With the pharmaceutical strategy, we want to create reliable research and innovation-friendly framework conditions and reduce bureaucratic hurdles

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.